Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy and safety profile in psoriasis
Janssen Biotech’s psoriasis drug wins FDA’s approval Disappointment as government delays pharma-friendly policies The government’s Accelerated Access Review (AAR) was supposed to herald a new age of innovation in the NHS, cutting drug development times and encouraging the use of novel medicines and treatments. But a new set of policies from the government ...... J&Js psoriasis drug faces crowded market after US approval Johnson & Johnson has won US approval for its new psoriasis drug, taking on the likes of Novartis, Eli Lilly and Valeant in an increasingly crowded market. The FDA has backed guselkumab, which will be branded as Tremfya, for adults with modera..... Novo Nordisk and Glooko launch diabetes management app New digital health partners Novo Nordisk and Glooko have released their first joint diabetes-focused app. The Cornerstones4Care (C4C) Powered by Glooko mobile app aims to help people manage their diabetes by letting them measure and track their bl..... Biosimilars manufacturers close in on Roche cancer blockbusters Roche’s blockbusters Herceptin and Avastin could face cheaper biosimilar competition in the US after FDA advisers unanimously backed their safety and efficacy. The regulator is not bound to follow the advice of its advisers – but it usually do...... Brexit could cause drug supply chaos, industry warns Leaders from associations representing the entire EU and UK pharmaceutical sector have written a joint letter to chief negotiators warning of the potential impact of an 'unorderly' Brexit on the drug supply chain. The pharma leaders warned that ...... IBM Watson impresses in brain tumour analysis IBM is busy applying its Watson AI to as many health arenas as possible and it looks like cancer genomic sequencing could be its next big market. In a new proof-of-concept study testing a beta version of its genomic sequencing-specific version...... AZ CEO set to take charge at Teva - report A press report has suggested AstraZeneca’s chief executive Pascal Soriot is set to leave and take the helm at Israel’s troubled Teva, sparking speculation about the outcome of a key lung cancer immunotherapy trial. The Israeli financial websi...... Novartis close to first-ever CAR-T approval after unanimous vote Novartis’ groundbreaking cancer T-cell therapy CTL019 has won unanimous backing from advisers to the FDA, paving the way for approval in the coming months. There had been concerns that the expert panel would query the drug's safety and the reli...... Mylan/Biocon Herceptin biosimilar faces EU delay Mylan and Biocon’s Herceptin biosimilar has hit problems in Europe after regulators called for improvements at its manufacturing plant. The European setback comes just ahead of a red letter day at the FDA. Its Oncologic Drugs Advisory Commit...... Google launches AI venture fund Google is looking to invest in artificial intelligence startups through its new venture fund, Gradient Ventures. The fund will provide support for startups struggling to overcome engineering challenges in relation to the creation of AI products......
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |